

 BIOGRAPHY OF KAREN A. DAWES
BIOGRAPHY OF KAREN A. DAWES


 
 
 Karen A. Dawes  (MBA, Harvard University - concentration in
Karen A. Dawes  (MBA, Harvard University - concentration in
 marketing and corporate strategy; MA & BA, Simmons College -
marketing and corporate strategy; MA & BA, Simmons College - 
 English and Communications is the President and Founder of
English and Communications is the President and Founder of
 Knowledgeable Decisions, LLC.  With 20+ years of commercial
Knowledgeable Decisions, LLC.  With 20+ years of commercial
 and executive management experience in the BioPharma industry,
and executive management experience in the BioPharma industry,
 Karen brings to clients a valuable and unique combination of
Karen brings to clients a valuable and unique combination of
 competencies.
competencies.
 Karen's industry experience began with 10 years of commercial
Karen's industry experience began with 10 years of commercial
 and executive management at Pfizer, where she gained increasing
and executive management at Pfizer, where she gained increasing
 responsibility in product management, development, and strategy
responsibility in product management, development, and strategy
 leading to her position as Vice-President, Marketing, Pratt Division.
leading to her position as Vice-President, Marketing, Pratt Division.
 Karen then moved to biotech pioneer Genetics Institute (GI), where, as
Karen then moved to biotech pioneer Genetics Institute (GI), where, as 
 Chief Commercial Officer, she built the company's initial commercial
Chief Commercial Officer, she built the company's initial commercial
 operations including strategic and operational marketing, sales,
operations including strategic and operational marketing, sales, 
 medical affairs, public relations, and market research.  At GI she and
medical affairs, public relations, and market research.  At GI she and
 her team launched the company's first two products - BeneFix for
her team launched the company's first two products - BeneFix for
 Factor IX replacement in hemophilia and Neumega for the treatment
Factor IX replacement in hemophilia and Neumega for the treatment
 of thrombocytopenia in cancer patients.
of thrombocytopenia in cancer patients.
 When GI was acquired by Wyeth, Karen moved to the new parent
When GI was acquired by Wyeth, Karen moved to the new parent
 company as Senior Vice-President, Global Strategic Marketing with
company as Senior Vice-President, Global Strategic Marketing with
 responsibility for strategic product development and global marketing.
responsibility for strategic product development and global marketing.
 In 1998, Karen moved to Bayer Corporation as Division Head for the
In 1998, Karen moved to Bayer Corporation as Division Head for the
 company's $2 billion U.S. Pharmaceuticals Division.  She founded
company's $2 billion U.S. Pharmaceuticals Division.  She founded
 Knowledgeable Decisions in 2003.
Knowledgeable Decisions in 2003.
 Throughout her career, Karen has been a key player in the
Throughout her career, Karen has been a key player in the
 successful development, launch, and marketing of products in the
successful development, launch, and marketing of products in the
 Cardiovascular, Metabolic, Infectious Disease, CNS, Oncology, and
Cardiovascular, Metabolic, Infectious Disease, CNS, Oncology, and
 Women's and Men's Health areas, including five products that
Women's and Men's Health areas, including five products that
 each exceeded sales of $1 billion dollars.
each exceeded sales of $1 billion dollars.  
 Karen is Co-Chair of the Board of Directors of Repligen Corporation,
Karen is Co-Chair of the Board of Directors of Repligen Corporation,   and a member of the Boards of Directors of Depomed, Inc., Symbiomix              Therapetuics, and Medicines 360.  Karen is a frequent speaker to
     and a member of the Boards of Directors of Depomed, Inc., Symbiomix              Therapetuics, and Medicines 360.  Karen is a frequent speaker to


 
 
|  | ||||